Journal article
The reliability and validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in first-episode psychosis
Leanne Hides, Sue M Cotton, Gregor Berger, John Gleeson, Colin O'Donnell, Tina Proffitt, Patrick D McGorry, Dan I Lubman
ADDICTIVE BEHAVIORS | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2009
Abstract
AIMS: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is a brief, easily administered, valid and reliable screening instrument for all psychoactive substances in drug treatment and primary care settings. This study aims to determine the reliability and validity of the ASSIST for detecting substance use disorders in first-episode psychosis. PARTICIPANTS: Participants were 214 first-episode psychosis patients attending the Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne, Australia. MEASUREMENTS: Participants were administered the ASSIST, Alcohol Use Disorders Identification Test (AUDIT), the Severity of Dependence Scale (SDS) and the Brief Psychia..
View full abstractRelated Projects (1)
Grants
Awarded by Astra-Zeneca Australia
Awarded by Stanley Medical Research Institute
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The authors would like to acknowledge Mirabel McConchie, Melissa Kerr, Connie Markulev, Belinda Newman, Donna Gee, Kingsley Crisp, Tracey Pearce, Alicia Papas and Michaela O'Regan for their assistance with the conduct of the studies. Leanne Hides, Dan Lubman and Tina Proffitt are supported by the Colonial Foundation. The EPISODE 11 study was funded by an unrestricted grant from Eli Lilly via the Lilly Melbourne Academic Psychiatry Consortium. The QDFS and VIP studies were funded by Astra-Zeneca Australia (AU-SEA-0003; clinicaltrials.gov Identifier: NCT00449397), and the Stanley Medical Research Institute (SMRI 03T-472), respectively. These studies were also supported by the Colonial Foundation and a Program Grant from the National Health and Medical Research Council of Australia (ID 350241). The funding bodies and pharmaceutical companies had no involvement in the design or conduct of the study, or in the collection, analysis and interpretation of data, or preparation of the manuscript. There are no other declarations.